dc.contributor.author | Berben, Philippe | |
dc.contributor.author | Bauer-Brandl, Annette | |
dc.contributor.author | Brandl, Martin | |
dc.contributor.author | Faller, Bernard | |
dc.contributor.author | Flaten, Gøril Eide | |
dc.contributor.author | Jacobsen, Ann-Cathrine | |
dc.contributor.author | Brouwers, Joachim | |
dc.contributor.author | Augustijns, Patrick | |
dc.date.accessioned | 2019-01-16T13:03:26Z | |
dc.date.available | 2019-01-16T13:03:26Z | |
dc.date.issued | 2018-04-13 | |
dc.description.abstract | Cell-free permeation systems are gaining interest in drug discovery and development as tools to obtain a reliable prediction of passive intestinal absorption without the disadvantages associated with cell- or tissue-based permeability profiling. Depending on the composition of the barrier, cell-free permeation systems are classified into two classes including (i) biomimetic barriers which are constructed from (phospho)lipids and (ii) non-biomimetic barriers containing dialysis membranes. This review provides an overview of the currently available cell-free permeation systems including Parallel Artificial Membrane Permeability Assay (PAMPA), Phospholipid Vesicle-based Permeation Assay (PVPA), Permeapad®, and artificial membrane based systems (e.g. the artificial membrane insert system (AMI-system)) in terms of their barrier composition as well as their predictive capacity in relation to well-characterized intestinal permeation systems. Given the potential loss of integrity of cell-based permeation barriers in the presence of food components or pharmaceutical excipients, the superior robustness of cell-free barriers makes them suitable for the combined dissolution/permeation evaluation of formulations. While cell-free permeation systems are mostly applied for exploring intestinal absorption, they can also be used to evaluate non-oral drug delivery by adjusting the composition of the membrane. | en_US |
dc.description | Source at <a href= https://doi.org/10.1016/j.ejps.2018.04.016> https://doi.org/10.1016/j.ejps.2018.04.016 </a>. | en_US |
dc.identifier.citation | Berben, P., Bauer-Brandl, A., Brandl, M., Faller, B., Flaten, G.E., Jacobsen, A.C.,… Augustijns, P.(2018). Drug permeability profiling using cell-free permeation tools: Overview and applications. Journal of Pharmaceutical Sciences, 119,219-233. https://doi.org/10.1016/j.ejps.2018.04.016. | en_US |
dc.identifier.cristinID | FRIDAID 1625357 | |
dc.identifier.doi | 10.1016/j.ejps.2018.04.016 | |
dc.identifier.issn | 0928-0987 | |
dc.identifier.issn | 1879-0720 | |
dc.identifier.uri | https://hdl.handle.net/10037/14461 | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.journal | European Journal of Pharmaceutical Sciences | |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/FP7-JTI/115369/EU/Oral biopharmaceutics tools/ORBITO/. | en_US |
dc.rights.accessRights | openAccess | en_US |
dc.subject | VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Pharmacology: 728 | en_US |
dc.subject | VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728 | en_US |
dc.subject | Artificial membrane insert system (AMI-system) | en_US |
dc.subject | Oral drug delivery | en_US |
dc.subject | Parallel artificial membrane permeability assay (PAMPA) | en_US |
dc.subject | Permeability | en_US |
dc.subject | Permeapad | en_US |
dc.subject | Phospholipid vesicle-based permeation assay (PVPA) | en_US |
dc.title | Drug permeability profiling using cell-free permeation tools: Overview and applications | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |